Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Ralph H. Johnson VA Medical Center AstraZeneca |
---|---|
Information provided by: | Ralph H. Johnson VA Medical Center |
ClinicalTrials.gov Identifier: | NCT00237393 |
The purpose of the study is to determine if quetiapine is effective in the treatment of PTSD.
Condition | Intervention | Phase |
---|---|---|
PTSD |
Drug: Quetiapine Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD |
Enrollment: | 80 |
Study Start Date: | August 2003 |
Study Completion Date: | December 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Quetiapine
|
Drug: Quetiapine
Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
|
2: Placebo Comparator |
Drug: Placebo
Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
|
Objective: To assess the impact of quetiapine on core PTSD symptoms and associated psychiatric comorbidity including depressive and positive and negative psychotic symptoms.
Research Design: 12-week, double-blind, placebo-controlled, randomized, fixed-flexible dose trial of quetiapine monotherapy.
Intervention: Eligible patients will be randomized to receive quetiapine starting at 25 mg daily or matching placebo. Dose adjustments (to a minimum of 50 mg or a maximum of 800 mg), will be made at the investigator's discretion and according to patient's clinical response.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Mexico | |
NM VA Healthcare System | |
Albuquerque, New Mexico, United States, 87108 | |
United States, South Carolina | |
Ralph H. Johnson VAMC | |
Charleston, South Carolina, United States, 29401 |
Principal Investigator: | Mark B Hamner, MD | Ralph H. Johnson VAMC/Medical University of South Carolina |
Responsible Party: | Ralph H. Johnson VA Medical Center ( Mark B. Hamner, MD ) |
Study ID Numbers: | 0058, HR-10762 |
Study First Received: | October 11, 2005 |
Last Updated: | February 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00237393 |
Health Authority: | United States: Federal Government |
PTSD Posttraumatic stress disorder Treatment Quetiapine |
Quetiapine Anxiety Disorders Mental Disorders |
Stress Disorders, Post-Traumatic Stress Stress Disorders, Traumatic |
Tranquilizing Agents Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |